Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors

ChangeBridge: Patent Grants - Pharma (A61K)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted patent US12595297B2 to In3Bio Ltd. covering methods for treating cancers driven by deregulated HER1/Human EGFR through combined administration of tyrosine kinase inhibitors (TKIs) and anti-EGF antibodies. The patent claims flexible dosing regimens for TKI (10-150 mg average daily dose) combined with antibody therapy administered weekly to monthly. The patent lists 5 claims and is classified under CPC codes A61K 38/179, A61K 39/001104, and related pharmaceutical compositions.

View original document View source feed page

What changed

The USPTO issued patent grant US12595297B2 to In3Bio Ltd. on April 7, 2026, covering combination therapy methods for EGFR-driven cancers using tyrosine kinase inhibitors and anti-EGF antibodies. The patent protects a flexible dosing regimen combining continuous TKI administration (10-150 mg daily) with antibody therapy delivered weekly, bi-weekly, monthly, or at least three times monthly. The anti-EGF antibodies may be produced through active immunization or administered passively. The patent originated from application 15073021 filed March 17, 2016.

For pharmaceutical and biotechnology companies developing targeted cancer therapies, this patent establishes IP protection for combination approaches targeting the EGF/EGFR pathway alongside tyrosine kinase inhibition. Entities conducting R&D in HER1/EGFR-driven cancers should evaluate potential licensing needs or design-around considerations. The patent's broad claim scope covering both active and passive antibody administration may capture multiple implementation approaches.

What to do next

Monitor for updates
Review patent claims for potential licensing opportunities

Source document (simplified)

← USPTO Patent Grants

Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors

Grant US12595297B2 Kind: B2 Apr 07, 2026

Assignee

In3Bio Ltd.

Inventors

Erik D'Hondt, Miguel Ángel Molina Vila

Abstract

A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.